2. Frazier OH, Myers TJ: Surgical therapy for severe heart failure. Curr Probl Cardiol 1998, 23:721?68. 3. Delgado HD, Rao V, Ross JR, Verma S, Smedira N: Mechanical circulatory assistance (State of Art). Circulation 2002, 106:2046?050. 4. Siegenthaler PM, Martin J, Loo A, Doenst T, Bothe W, Beyersdorf F: Implantation in the permanent jarvik-2000 left ventricular help device. JACC 2002, 39:1764?772. five. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Lengthy JW, Ascheim DD, Tierney AR, Levitan RG, Levitan RG, Watson JT, Ronan NS, Meier P: Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001, 345:1435?443. 6. Schmia MC, Gumpert AM, Kock WJ: Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther 2014, 14:183?95. 7. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, Hadri L, Yoneyama R, Hoshino K, Takewa Y, Sakata S, Peluso R, Zsebo K, Gwathmey JK, Tardif JC, Tanguay JF, Hajjar RJ: Reversal of cardiac dysfunction following long-term expression of SERCA2a by gene transfer within a pre-clinical model of heart failure. J Am Coll Cardiol 2008, 51(11):1112?119. 8. Rengo G, Lymperopoulous A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, Koch WJ: Myocardial adeno-associated serotype six BARKct gene therapy improves cardiac function and normalizes the neurhormonal axis in chronic heart failure. Circulation 2009, 119(1):89?8. 9. Giacca M, Zacchigna S: VEGF gene therapy:therapeutic angiogenesis in the clinic and beyond. Gene Ther 2012, 19(six):622?29. 10. Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S, Giacca M: Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012, 492(7249):376?81. 11. Wang W, Li W, Ma N, Steinhoff G: Non-viral gene delivery methods. Curr Pharm Biotechnology 2013, 14(1):46?0. 12. Su CH, Wu YJ, Wang HH, Yeh HI: Non-viral gene therapy targeting the cardiovascular method. Am J Physiol Heart Circ 2012, 303(six):629?38.BnO-PEG4-OH structure 13.Price of 6-Chloro-3-fluoro-2-methoxypyridine Katz MG, Swain JD, Tomasulo CE, Sumaroka M, Fargnoli A, Bridges CR: Existing Tactics for Myocardial Gene Delivery. J Mol Cell Cardiol 2011, 50(5):766?76. Epub 2010 Sep 15. 14. Katz MG, Fargnoli AS, Williams RD, Bridges CR: The road ahead: operating towards powerful clinical translation of myocardial gene therapies. Ther Deliv 2014, five(1):39?1. doi: 10.4155/tde.13.134. 15. Logeart D, Hatem SN, Heimburger M, Le Roux A, Michel JB, Mercadier JJ: Tips on how to optimize in vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures? Hum Gene Ther 2001, 12:1601?610. 16. Katz MG, Fargnoli AS, Williams RD, Bridges CR: Gene therapy for enhancing viral and nonviral vectors for cardiac illnesses: Current concepts and future applications. Hum Gene Ther 2013, 24(11):914?27.PMID:33525861 17. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ: Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase two trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in individuals with advanced heart failure. Circulation 2014, 124(3):304?13. doi: 10.1161/CIRCULATIONAHA.111.022889. Epub 2011 Jun 27. 18. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM: Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in big animals. Gene Ther 2008, 15(23):1550?557. 19. Kaye DM, Preovolos A, Marshall T, Byrne M, Hoshijima M,.